Sevikar HCT 40/5/12.5 tablets

Sevikar HCT is a specialized prescription medication used for the treatment of hypertension (high blood pressure). It is a triple-combination therapy consisting of three active ingredients: Olmesartan medoxomil (an angiotensin II receptor antagonist), Amlodipine (a calcium channel blocker), and Hydrochlorothiazide (a diuretic). This specific packaging, indicated by the 'AUST R' code, is marketed for the Australian healthcare sector.

The pharmaceutical brand was originally developed and patented by the Japanese company Daiichi Sankyo. In many international markets, including Australia and parts of Europe, the brand is managed through partnerships or subsidiaries. Organon, which is visible on the packaging, became the primary entity responsible for the distribution and management of these established brands following its spin-off from Merck & Co. (known as MSD outside the US and Canada) in 2021. Manufacturing typically occurs in specialized pharmaceutical facilities located in Germany to maintain high regulatory compliance for global distribution.